Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Receives Consensus Rating of “Buy” from Analysts

Shares of Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) have received a consensus recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company.

A number of equities research analysts have recently commented on RBGLY shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Reckitt Benckiser Group in a report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Reckitt Benckiser Group in a research note on Monday.

Reckitt Benckiser Group Stock Down 1.0%

RBGLY stock opened at $15.46 on Monday. The firm has a 50 day moving average price of $15.40 and a 200-day moving average price of $14.34. Reckitt Benckiser Group has a 52-week low of $11.73 and a 52-week high of $15.98. The company has a current ratio of 0.56, a quick ratio of 0.37 and a debt-to-equity ratio of 1.01.

Reckitt Benckiser Group Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, September 25th. Shareholders of record on Monday, August 11th were paid a $0.2106 dividend. This represents a dividend yield of 341.0%. The ex-dividend date of this dividend was Friday, August 8th.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.